Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study

Схожие документы

• Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
  по: Ghofrani, Hossein-Ardeschir, et al.
  Опубликовано: (2020)
• Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
  по: Benza, Raymond L., et al.
  Опубликовано: (2020)
• RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
  по: Hoeper, Marius M., et al.
  Опубликовано: (2017)
• Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies
  по: Thenappan, Thenappan, et al.
  Опубликовано: (2020)
• Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
  по: Stephan, Rosenkranz, et al.
  Опубликовано: (2015)